Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Stock Competitors & Peer Comparison
See IRWD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IRWD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IRWD | $3.48 | -7.82% | 578.3M | 4.49 | $0.78 | N/A |
| TAK | $19.72 | +1.36% | 62.2B | 14.16 | $1.39 | +3.59% |
| TEVA | $41.40 | +0.69% | 48.3B | 14.16 | $2.93 | N/A |
| HLN | $10.17 | +2.26% | 44.5B | 20.71 | $0.49 | +1.96% |
| ZTS | $79.73 | +1.67% | 32.8B | 12.06 | $6.58 | +2.65% |
| VTRS | $18.33 | +0.60% | 21.4B | 7.40 | $2.52 | +2.60% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.58 | +0.15% | 11.8B | 22.23 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.07 | +1.28% | 10.9B | 27.79 | $0.47 | +0.64% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
IRWD vs TAK Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TAK has a market cap of 62.2B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TAK trades at $19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TAK's P/E ratio is 14.16. In terms of profitability, IRWD's ROE is -0.57%, compared to TAK's ROE of +0.02%. Regarding short-term risk, IRWD is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
IRWD vs TEVA Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TEVA has a market cap of 48.3B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TEVA trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TEVA's P/E ratio is 14.16. In terms of profitability, IRWD's ROE is -0.57%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, IRWD is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TEVA's competition here
Haleon plc (NYSE: HLN)
IRWD vs HLN Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while HLN trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas HLN's P/E ratio is 20.71. In terms of profitability, IRWD's ROE is -0.57%, compared to HLN's ROE of +0.10%. Regarding short-term risk, IRWD is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
IRWD vs ZTS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ZTS trades at $79.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ZTS's P/E ratio is 12.06. In terms of profitability, IRWD's ROE is -0.57%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, IRWD is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
IRWD vs VTRS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while VTRS trades at $18.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas VTRS's P/E ratio is 7.40. In terms of profitability, IRWD's ROE is -0.57%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, IRWD is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
IRWD vs ITCI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ITCI's P/E ratio is -180.64. In terms of profitability, IRWD's ROE is -0.57%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, IRWD is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
IRWD vs ELAN Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ELAN trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ELAN's P/E ratio is 22.23. In terms of profitability, IRWD's ROE is -0.57%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, IRWD is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
IRWD vs CTLT Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CTLT's P/E ratio is -27.84. In terms of profitability, IRWD's ROE is -0.57%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, IRWD is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
IRWD vs RDY Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while RDY trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas RDY's P/E ratio is 27.79. In terms of profitability, IRWD's ROE is -0.57%, compared to RDY's ROE of +0.09%. Regarding short-term risk, IRWD is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
IRWD vs ALKS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ALKS trades at $42.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ALKS's P/E ratio is 43.39. In terms of profitability, IRWD's ROE is -0.57%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, IRWD is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
IRWD vs LNTH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while LNTH trades at $100.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas LNTH's P/E ratio is 16.76. In terms of profitability, IRWD's ROE is -0.57%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, IRWD is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
IRWD vs AMRX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, AMRX has a market cap of 6.1B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while AMRX trades at $19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas AMRX's P/E ratio is 21.31. In terms of profitability, IRWD's ROE is -0.57%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, IRWD is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
IRWD vs RGC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, RGC has a market cap of 4.8B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while RGC trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas RGC's P/E ratio is -959.00. In terms of profitability, IRWD's ROE is -0.57%, compared to RGC's ROE of -1.61%. Regarding short-term risk, IRWD is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
IRWD vs INDV Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, INDV has a market cap of 4B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while INDV trades at $33.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas INDV's P/E ratio is 8.89. In terms of profitability, IRWD's ROE is -0.57%, compared to INDV's ROE of -2.16%. Regarding short-term risk, IRWD is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
IRWD vs HCM Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while HCM trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas HCM's P/E ratio is 135.88. In terms of profitability, IRWD's ROE is -0.57%, compared to HCM's ROE of +0.01%. Regarding short-term risk, IRWD is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
IRWD vs ALVOW Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, IRWD's ROE is -0.57%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, IRWD is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
IRWD vs BHC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while BHC trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas BHC's P/E ratio is 1.60. In terms of profitability, IRWD's ROE is -0.57%, compared to BHC's ROE of +0.89%. Regarding short-term risk, IRWD is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check BHC's competition here
Perrigo Company plc (NYSE: PRGO)
IRWD vs PRGO Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while PRGO trades at $16.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas PRGO's P/E ratio is 6.65. In terms of profitability, IRWD's ROE is -0.57%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, IRWD is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
IRWD vs DCPH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas DCPH's P/E ratio is -11.58. In terms of profitability, IRWD's ROE is -0.57%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, IRWD is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check DCPH's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
IRWD vs SUPN Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, SUPN has a market cap of 2.2B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while SUPN trades at $39.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas SUPN's P/E ratio is 12.38. In terms of profitability, IRWD's ROE is -0.57%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, IRWD is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check SUPN's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
IRWD vs AVDL Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, IRWD's ROE is -0.57%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, IRWD is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
IRWD vs EMBCV Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas EMBCV's P/E ratio is N/A. In terms of profitability, IRWD's ROE is -0.57%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, IRWD is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
IRWD vs DVAX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas DVAX's P/E ratio is -41.89. In terms of profitability, IRWD's ROE is -0.57%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, IRWD is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
IRWD vs ALVO Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ALVO trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ALVO's P/E ratio is -8.47. In terms of profitability, IRWD's ROE is -0.57%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, IRWD is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
IRWD vs TRLV Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TRLV trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TRLV's P/E ratio is -4.07. In terms of profitability, IRWD's ROE is -0.57%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, IRWD is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
IRWD vs ANIP Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ANIP trades at $72.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ANIP's P/E ratio is 8.79. In terms of profitability, IRWD's ROE is -0.57%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, IRWD is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
IRWD vs TARO Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TARO's P/E ratio is 30.05. In terms of profitability, IRWD's ROE is -0.57%, compared to TARO's ROE of +0.03%. Regarding short-term risk, IRWD is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
IRWD vs PAHC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while PAHC trades at $39.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas PAHC's P/E ratio is 13.25. In terms of profitability, IRWD's ROE is -0.57%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, IRWD is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
IRWD vs PCRX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while PCRX trades at $36.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas PCRX's P/E ratio is 13.98. In terms of profitability, IRWD's ROE is -0.57%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, IRWD is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
IRWD vs ETON Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ETON trades at $49.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ETON's P/E ratio is 132.34. In terms of profitability, IRWD's ROE is -0.57%, compared to ETON's ROE of +0.40%. Regarding short-term risk, IRWD is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
IRWD vs CRON Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CRON trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CRON's P/E ratio is 16.44. In terms of profitability, IRWD's ROE is -0.57%, compared to CRON's ROE of +0.06%. Regarding short-term risk, IRWD is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
IRWD vs AMPH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while AMPH trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas AMPH's P/E ratio is 8.83. In terms of profitability, IRWD's ROE is -0.57%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, IRWD is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
IRWD vs HROW Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while HROW trades at $28.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas HROW's P/E ratio is -27.56. In terms of profitability, IRWD's ROE is -0.57%, compared to HROW's ROE of -1.04%. Regarding short-term risk, IRWD is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
IRWD vs PETQ Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas PETQ's P/E ratio is 83.73. In terms of profitability, IRWD's ROE is -0.57%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, IRWD is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
IRWD vs COLL Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, COLL has a market cap of 755M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while COLL trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas COLL's P/E ratio is 2.91. In terms of profitability, IRWD's ROE is -0.57%, compared to COLL's ROE of +0.16%. Regarding short-term risk, IRWD is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check COLL's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
IRWD vs BDSI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas BDSI's P/E ratio is 6.82. In terms of profitability, IRWD's ROE is -0.57%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, IRWD is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
IRWD vs EVO Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, EVO has a market cap of 491.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while EVO trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas EVO's P/E ratio is -1.96. In terms of profitability, IRWD's ROE is -0.57%, compared to EVO's ROE of -0.27%. Regarding short-term risk, IRWD is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
IRWD vs AQST Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, AQST has a market cap of 473.8M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while AQST trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas AQST's P/E ratio is -5.81. In terms of profitability, IRWD's ROE is -0.57%, compared to AQST's ROE of +2.44%. Regarding short-term risk, IRWD is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
IRWD vs EOLS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, EOLS has a market cap of 468.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while EOLS trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas EOLS's P/E ratio is -22.45. In terms of profitability, IRWD's ROE is -0.57%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, IRWD is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
IRWD vs KMDA Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, KMDA has a market cap of 446.6M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while KMDA trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas KMDA's P/E ratio is 20.37. In terms of profitability, IRWD's ROE is -0.57%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, IRWD is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
IRWD vs TKNO Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TKNO has a market cap of 380.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TKNO trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TKNO's P/E ratio is -22.84. In terms of profitability, IRWD's ROE is -0.57%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, IRWD is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
IRWD vs TLRY Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TLRY has a market cap of 340M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TLRY trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TLRY's P/E ratio is -2.17. In terms of profitability, IRWD's ROE is -0.57%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, IRWD is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
IRWD vs EBS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, EBS has a market cap of 326.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while EBS trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas EBS's P/E ratio is 4.43. In terms of profitability, IRWD's ROE is -0.57%, compared to EBS's ROE of -0.36%. Regarding short-term risk, IRWD is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
IRWD vs CGC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CGC has a market cap of 301.7M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CGC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CGC's P/E ratio is -1.60. In terms of profitability, IRWD's ROE is -0.57%, compared to CGC's ROE of -0.33%. Regarding short-term risk, IRWD is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
IRWD vs ALIM Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ALIM's P/E ratio is 5.28. In terms of profitability, IRWD's ROE is -0.57%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, IRWD is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ALIM's competition here
Glass House Brands Inc (NYSE: GLAS)
IRWD vs GLAS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, GLAS has a market cap of 279.8M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while GLAS trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas GLAS's P/E ratio is -5.68. In terms of profitability, IRWD's ROE is -0.57%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, IRWD is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check GLAS's competition here
Landec Corporation (NASDAQ: LNDC)
IRWD vs LNDC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas LNDC's P/E ratio is -4.04. In terms of profitability, IRWD's ROE is -0.57%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, IRWD is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
IRWD vs ACB Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ACB has a market cap of 252.6M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ACB trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ACB's P/E ratio is -2.88. In terms of profitability, IRWD's ROE is -0.57%, compared to ACB's ROE of -0.21%. Regarding short-term risk, IRWD is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
IRWD vs LFCR Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, LFCR has a market cap of 241.8M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while LFCR trades at $6.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas LFCR's P/E ratio is -5.02. In terms of profitability, IRWD's ROE is -0.57%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, IRWD is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
IRWD vs TYHT Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TYHT's P/E ratio is -1.61. In terms of profitability, IRWD's ROE is -0.57%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, IRWD is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
IRWD vs SIGA Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, SIGA has a market cap of 227.8M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while SIGA trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas SIGA's P/E ratio is 11.74. In terms of profitability, IRWD's ROE is -0.57%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, IRWD is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
IRWD vs REPH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas REPH's P/E ratio is -8.04. In terms of profitability, IRWD's ROE is -0.57%, compared to REPH's ROE of -0.22%. Regarding short-term risk, IRWD is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
IRWD vs THTX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas THTX's P/E ratio is -28.83. In terms of profitability, IRWD's ROE is -0.57%, compared to THTX's ROE of +0.36%. Regarding short-term risk, IRWD is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
IRWD vs ASRT Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ASRT's P/E ratio is -7.10. In terms of profitability, IRWD's ROE is -0.57%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, IRWD is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
IRWD vs DERM Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, DERM has a market cap of 139.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while DERM trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas DERM's P/E ratio is -22.52. In terms of profitability, IRWD's ROE is -0.57%, compared to DERM's ROE of -0.20%. Regarding short-term risk, IRWD is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
IRWD vs CRDL Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CRDL trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CRDL's P/E ratio is -4.38. In terms of profitability, IRWD's ROE is -0.57%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, IRWD is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
IRWD vs OGI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, OGI has a market cap of 130.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while OGI trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas OGI's P/E ratio is 2.09. In terms of profitability, IRWD's ROE is -0.57%, compared to OGI's ROE of +0.21%. Regarding short-term risk, IRWD is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check OGI's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
IRWD vs ORGO Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ORGO has a market cap of 128.6M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ORGO trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ORGO's P/E ratio is 33.32. In terms of profitability, IRWD's ROE is -0.57%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, IRWD is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
IRWD vs SCTL Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas SCTL's P/E ratio is -7.86. In terms of profitability, IRWD's ROE is -0.57%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, IRWD is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
IRWD vs BGM Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, BGM has a market cap of 110.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while BGM trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas BGM's P/E ratio is -1.81. In terms of profitability, IRWD's ROE is -0.57%, compared to BGM's ROE of -0.05%. Regarding short-term risk, IRWD is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check BGM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
IRWD vs CPIX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CPIX has a market cap of 107.6M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CPIX trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CPIX's P/E ratio is -17.95. In terms of profitability, IRWD's ROE is -0.57%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, IRWD is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
IRWD vs PROC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas PROC's P/E ratio is 1.53. In terms of profitability, IRWD's ROE is -0.57%, compared to PROC's ROE of -2.22%. Regarding short-term risk, IRWD is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
IRWD vs OPTN Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas OPTN's P/E ratio is -4.42. In terms of profitability, IRWD's ROE is -0.57%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, IRWD is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
IRWD vs ZOM Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ZOM's P/E ratio is -1.62. In terms of profitability, IRWD's ROE is -0.57%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, IRWD is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
IRWD vs GRVI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas GRVI's P/E ratio is 26.05. In terms of profitability, IRWD's ROE is -0.57%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, IRWD is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
IRWD vs ZYNE Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, IRWD's ROE is -0.57%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, IRWD is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
IRWD vs ZYBT Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ZYBT has a market cap of 69.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ZYBT trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ZYBT's P/E ratio is -7.30. In terms of profitability, IRWD's ROE is -0.57%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, IRWD is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
IRWD vs SSIC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas SSIC's P/E ratio is 11.93. In terms of profitability, IRWD's ROE is -0.57%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, IRWD is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
IRWD vs VLNS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas VLNS's P/E ratio is -1.03. In terms of profitability, IRWD's ROE is -0.57%, compared to VLNS's ROE of N/A. Regarding short-term risk, IRWD is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
IRWD vs DRRX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas DRRX's P/E ratio is -4.44. In terms of profitability, IRWD's ROE is -0.57%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, IRWD is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
IRWD vs TLPH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TLPH's P/E ratio is -4.00. In terms of profitability, IRWD's ROE is -0.57%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, IRWD is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
IRWD vs INCR Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, INCR has a market cap of 54.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while INCR trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas INCR's P/E ratio is -4.81. In terms of profitability, IRWD's ROE is -0.57%, compared to INCR's ROE of -0.09%. Regarding short-term risk, IRWD is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
IRWD vs JUPW Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas JUPW's P/E ratio is -2.41. In terms of profitability, IRWD's ROE is -0.57%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, IRWD is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
IRWD vs QLI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas QLI's P/E ratio is -4.92. In terms of profitability, IRWD's ROE is -0.57%, compared to QLI's ROE of -0.16%. Regarding short-term risk, IRWD is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
IRWD vs HEXO Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas HEXO's P/E ratio is -0.26. In terms of profitability, IRWD's ROE is -0.57%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, IRWD is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
IRWD vs RMTI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, RMTI has a market cap of 29.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while RMTI trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas RMTI's P/E ratio is -5.54. In terms of profitability, IRWD's ROE is -0.57%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, IRWD is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
IRWD vs CPHI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CPHI has a market cap of 29.4M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CPHI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CPHI's P/E ratio is -1.59. In terms of profitability, IRWD's ROE is -0.57%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, IRWD is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CPHI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
IRWD vs SHPH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, SHPH has a market cap of 24.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while SHPH trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas SHPH's P/E ratio is -0.24. In terms of profitability, IRWD's ROE is -0.57%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, IRWD is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
IRWD vs CYTH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CYTH's P/E ratio is -0.80. In terms of profitability, IRWD's ROE is -0.57%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, IRWD is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
IRWD vs AYTU Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, AYTU has a market cap of 22.1M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while AYTU trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas AYTU's P/E ratio is -1.72. In terms of profitability, IRWD's ROE is -0.57%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, IRWD is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
IRWD vs TXMD Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, TXMD has a market cap of 22M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while TXMD trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas TXMD's P/E ratio is 96.79. In terms of profitability, IRWD's ROE is -0.57%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, IRWD is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TXMD's competition here
Optimi Health Corp. (NASDAQ: OPTH)
IRWD vs OPTH Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, OPTH has a market cap of 19.4M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while OPTH trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas OPTH's P/E ratio is -2.17. In terms of profitability, IRWD's ROE is -0.57%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, IRWD is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check OPTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
IRWD vs EVOK Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas EVOK's P/E ratio is -7.97. In terms of profitability, IRWD's ROE is -0.57%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, IRWD is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
IRWD vs ACRX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ACRX's P/E ratio is -0.31. In terms of profitability, IRWD's ROE is -0.57%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, IRWD is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
IRWD vs CABR Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, CABR has a market cap of 11.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while CABR trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas CABR's P/E ratio is -1.58. In terms of profitability, IRWD's ROE is -0.57%, compared to CABR's ROE of -3.86%. Regarding short-term risk, IRWD is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
IRWD vs AGRX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas AGRX's P/E ratio is -0.89. In terms of profitability, IRWD's ROE is -0.57%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, IRWD is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
IRWD vs NLTX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas NLTX's P/E ratio is -0.28. In terms of profitability, IRWD's ROE is -0.57%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, IRWD is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
IRWD vs LCI Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas LCI's P/E ratio is -0.04. In terms of profitability, IRWD's ROE is -0.57%, compared to LCI's ROE of +1.66%. Regarding short-term risk, IRWD is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
IRWD vs ADMP Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ADMP's P/E ratio is -0.08. In terms of profitability, IRWD's ROE is -0.57%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, IRWD is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ADMP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
IRWD vs INM Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, INM has a market cap of 7.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while INM trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas INM's P/E ratio is -0.43. In terms of profitability, IRWD's ROE is -0.57%, compared to INM's ROE of -1.35%. Regarding short-term risk, IRWD is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check INM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
IRWD vs SNOA Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, SNOA has a market cap of 5.5M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while SNOA trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas SNOA's P/E ratio is -1.04. In terms of profitability, IRWD's ROE is -0.57%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, IRWD is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
IRWD vs MNK Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas MNK's P/E ratio is -0.44. In terms of profitability, IRWD's ROE is -0.57%, compared to MNK's ROE of -0.36%. Regarding short-term risk, IRWD is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
IRWD vs FLGC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas FLGC's P/E ratio is -0.19. In terms of profitability, IRWD's ROE is -0.57%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, IRWD is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check FLGC's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
IRWD vs GELS Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, GELS has a market cap of 4.2M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while GELS trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas GELS's P/E ratio is -1.05. In terms of profitability, IRWD's ROE is -0.57%, compared to GELS's ROE of -0.25%. Regarding short-term risk, IRWD is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
IRWD vs YCBD Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, YCBD has a market cap of 3.8M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while YCBD trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas YCBD's P/E ratio is -0.84. In terms of profitability, IRWD's ROE is -0.57%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, IRWD is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check YCBD's competition here
Akanda Corp. (NASDAQ: AKAN)
IRWD vs AKAN Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, AKAN has a market cap of 2.9M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while AKAN trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas AKAN's P/E ratio is -0.03. In terms of profitability, IRWD's ROE is -0.57%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, IRWD is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
IRWD vs PLXP Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas PLXP's P/E ratio is -0.22. In terms of profitability, IRWD's ROE is -0.57%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, IRWD is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
IRWD vs UPC Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while UPC trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas UPC's P/E ratio is -0.49. In terms of profitability, IRWD's ROE is -0.57%, compared to UPC's ROE of -0.03%. Regarding short-term risk, IRWD is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
IRWD vs ATNX Comparison October 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 578.3M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, IRWD is priced at $3.48 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 4.49, whereas ATNX's P/E ratio is -0.02. In terms of profitability, IRWD's ROE is -0.57%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, IRWD is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ATNX's competition here